Characterisation of a musculoskeletal syndrome of enthesitis and arthritis in patients with Atopic Dermatitis treated with Dupilumab, an IL-4/13 inhibitor.

We report a new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis in some patients receiving the IL-4 Receptor antagonist, dupilumab. This response to a cytokine-targeted therapy provides key insights into the pathogenesis of enthesitis. This article is protected by copyright. All rights reserved.